1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Genomics BioSci & Tech. Co., Ltd.

Genomics BioSci & Tech. Co., Ltd.

TTWSE:4195
14.85
TWD
-0.30
(-1.98%)
-0.36EPS
1.25BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5.03
6.07
7.17
6.19
7.2
6.15
7
7.26
6.42
6.62
5.57
7.14
9.78
4.27
Basic EPS, GAAP
-1.48
-0.62
-0.53
-0.73
-0.59
-0.99
1.39
0.01
0.31
1.13
-2.36
-3.08
-0.54
-0.14
Free Cash Flow per Basic Share
-1.53
-2.81
1.63
-1.61
-1.43
0.64
0.93
-1.07
-2.02
-1.82
-3.48
-4.21
-2.37
-1
Dividend per Share
0.42
- -
- -
- -
- -
- -
- -
1.14
- -
- -
0.1
- -
- -
- -
Book Value per Share
10.76
12.68
11.35
11.22
10.94
9.94
11.33
11.01
11.13
12.19
10.57
7.57
7.04
8.32
Tangible Book Value per Share
10.67
12.61
11.3
10.51
10.14
9.27
11.32
10.95
11.11
12.18
10.54
7.49
6.95
8.2
Basic Weighted Avg Shares
46
52
56
61
61
61
61
61
61
63
71
72
72
75
Sales/Revenue/Turnover
230
317
401
376
440
375
428
443
390
419
396
518
708
320
Operating Margin (%)
-29.16
-12.44
-8.69
-12.84
-9.29
-10.91
3.03
2.4
-7.5
-7.56
-21.46
-27.09
-10.53
-26.47
Depreciation Expense
16
20
26
36
35
40
39
35
34
33
40
63
76
42
Net Income, GAAP
-68
-33
-30
-44
-36
-61
85
1
19
72
-168
-223
-39
-10
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
34.44
- -
- -
0.92
- -
- -
- -
- -
Profit Margin (%)
-29.42
-10.26
-7.41
-11.8
-8.22
-16.13
19.86
0.14
4.81
17.09
-42.43
-43.1
-5.57
-3.25
Working Capital
382
375
346
362
406
375
380
529
157
329
326
232
106
182
LT Debt
96
66
63
59
56
52
49
59
79
162
222
337
311
278
Total Equity
565
664
637
709
744
675
692
908
679
789
766
641
582
749
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
0.75
- -
-3.2
-3.72
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
12.95
- -
3.02
8.25
- -
- -
- -
- -
Return on Common Equity (%)
-13.5
-5.3
-4.57
-6.71
-5.34
-9.5
13.08
0.09
2.77
9.75
-21.62
-33.95
-7.45
-1.77

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
317
347
259
LT Borrowings
301
286
271
LT Finance Leases
9
8
8
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
72
72
80
Market Capitalization
- -
- -
1,252

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
639
571
607
Cash, Cash Equivalents & STI
199
153
210
Accounts Receivable, Net
166
149
143
Inventories
236
237
215
Total Current Liabilities
533
500
424
Payables & Accruals
- -
- -
- -
ST Debt
317
347
259
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.33%
-7.49%
-9.16%
Free Cash Flow
-35.47%
35.19%
-43.76%
Net Income, GAAP
258.38%
564.98%
-82.33%
Sales/Revenue/Turnover
7.12%
11.5%
36.86%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
133
120
518
2025
122
189
178
220
708
2026
152
168
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
-1.18
-0.95
-3.08
2025
-0.34
- -
0.13
-0.34
-0.54
2026
-0.54
0.37
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Shang-Hui Wu
Full Time Employees
120
Sector
Health technology
Industry
Biotechnology
Address
No.100, Xintai 5th Road New Taipei Taiwan
IPO Date
May 11, 2026
Website
genomics.com.tw
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Genomics BioSci & Tech. Co., Ltd. operates as a leading biotechnology company specializing in genomics and genetic analysis, headquartered in New Taipei City, Taiwan, and founded in 2001. The company offers comprehensive sequencing services, including first, second, and third-generation sequencing platforms; regular DNA sequencing; complex sequence and TAF certified sequencing; RNA and gene expression sequencing; microbial sequencing; and genomic sequencing services covering genome-level, targeted, gene regulation, and metagenomics. Its synthesis services comprise oligonucleotide, probe, RNA, gene, and peptide synthesis. Genomics also provides proteomic services, including Olink proteomic assays for protein biomarker screening, and extensive testing and analytical services such as sample preparation, gene expression analysis, genotyping, DNA methylation analysis, and microbial identification. Additionally, the company has a contract development and manufacturing segment (CDMO) supporting vaccine adjuvant and active pharmaceutical ingredient (API) development, from pre-clinical to clinical phases, catering to the vaccine adjuvant, cellular, and gene therapy industries. Recent strategic developments include signing an exclusive agency contract with Thermo Fisher for the Taiwan region, acquiring a 16% stake in Wyzer Biosciences to enter the U.S. market, launching its first nucleic acid adjuvant product with planned GMP plant inspection, and demonstrating milestone outcomes of its PIC/S GMP nucleic acid and peptide pilot plant at BIO Asia-Taiwan. The company has expanded its CDMO offerings by transforming nucleic acid synthesis services from academic research provision to raw material supply for high-grade detection probe kits and nucleic medications, forming strategic alliances to develop new products, broadening clinical applications, and venturing into precision gene therapy and cancer therapy as integrated service solutions. Genomics BioSci & Tech serves a diverse customer base including research institutions, biotechnology companies, and medical centers, predominantly operating in Taiwan with growing international presence through partnerships and equity investments. The company maintains advanced proprietary production lines and strong bioinformatics capabilities to support its full-service pipeline from production to data analysis.